Abstract:Background: Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist known to delay gastric emptying. Despite a growing body of evidence, its peri-operative safety profile remains uncertain, particularly with regard to the risk of increased residual gastric content and aspiration of gastric contents during anaesthesia. We hypothesised that semaglutide interruption of ≤ 10 days before elective surgical procedures is insufficient to reduce or normalise the residual gastric content, despite fasting intervals that comply with current guidelines. Methods: In this prospective observational study, we recruited patients who received pre-operative once-weekly subcutaneous semaglutide within 10 days of the procedure (semaglutide group) and control patients who had not been exposed to semaglutide (non-semaglutide group). On the day of surgery, all patients underwent pre-operative point-of-care gastric ultrasound to evaluate their residual gastric content. Increased residual gastric content was defined as any solid content or > 1.5 ml.kg-1 of clear fluids as assessed by gastric ultrasound. Results: We recruited 220 patients, 107 in the semaglutide group and 113 in the non-semaglutide group. Increased residual gastric content was found in 43/107 patients (40%) in the semaglutide group and 3/113 (3%) in the non-semaglutide group (p < 0.001). In propensity-weighted analysis, semaglutide use (OR 36.97, 95%CI 16.54-99.32), age (OR 0.95, 95%CI 0.93-0.98) and male sex (OR 2.28, 95%CI 1.29-4.06) were significantly associated with increased residual gastric content. There were no cases of pulmonary aspiration of gastric contents. Conclusion: Pre-operative semaglutide use within 10 days of elective surgical procedures was independently associated with increased risk of residual gastric content on pre-operative gastric ultrasound assessment.

Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report

Anesthesia Considerations for a Patient on Semaglutide and Delayed Gastric Emptying

Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss

Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide

Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: a case report with tomographic evidence

Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report

Point-of-Care Ultrasound Aids in the Management of Patient Taking Semaglutide Before Surgery: A Case Report

S4698 Esophageal Obstruction Secondary to Severe Gastroduodenal Retention in the Setting of Recent Semaglutide Initiation

Pulmonary aspiration during upper endoscopy in a patient prescribed semaglutide

Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study

Evaluation of gastric content in fasting patient during semaglutide use: an observational study

GLP-1 Receptor Agonists - An Anaesthesiologist’s Perspective – A Comprehensive Review

S4691 Some Semaglutide Side Effect: Ileus as a Complication of a GLP-1 Receptor Analog

Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty

Challenges with a glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors

Glucagon-Like Peptide-1 Receptor Agonists During Electroconvulsive Therapy

S927 Risk of Gastric Food Retention With Glucagon-like Peptide 1 Receptor Agonists versus Diabetes Mellitus: A Case-Control Study From a Large Tertiary Care Health System

Acute Pancreatitis Likely Due to Semaglutide

Clinical Outcomes and Safety of Upper Endoscopy While on Glucagon-Like Peptide-1 Receptor Agonists

Glucagon-Like Peptide-1 Receptor Agonists During Electroconvulsive Therapy: Case Report With Evolving Concerns and Management Considerations

Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist